heart disease
The partnership will focus on building AI tools that accelerate heart disease and cancer detection with the aim of reducing diagnostic turnaround times.
A Singaporean startup leverages Asian-specific databases in making heart disease risk assessments.
The funding comes more than a year after the company closed an oversubscribed $31.4 million Series B round.
The company will use the funds to expand its commercial growth and clinical-evidence generation.
The company is also recruiting a CEO in the US.
Powered by AI, it has over 80% accuracy in detecting valvular heart disease.
Clinical research is set to verify the technology's effectiveness in estimating abnormal heart movements.
The risk assessment tool can potentially determine if plaque build-up has narrowed a patient's coronary arteries.
The AHA says future developments in health technology aimed at seniors should address this demographic’s barriers to adoption.
From mobile ECGs to tele-rehabilitation to defibrillator delivery drones, a range of new data was on display at the American Heart Association Scientific Sessions 2019.